Progress on interleukin-27 in tumor immunity.
- Author:
Jia HE
1
;
Qing-qing WANG
1
Author Information
1. Institute of Immunology, Zhejiang University School of Medicine, Hangzhou 310058, China.
- Publication Type:Journal Article
- MeSH:
Dendritic Cells;
Humans;
Interleukin-27;
immunology;
Killer Cells, Natural;
Macrophages;
Neoplasms;
immunology;
T-Lymphocyte Subsets;
T-Lymphocytes, Cytotoxic
- From:
Journal of Zhejiang University. Medical sciences
2015;44(2):223-228
- CountryChina
- Language:Chinese
-
Abstract:
As a member of IL-6/IL-12 cytokine family, IL-27 is a heterodimeric cytokine composed of the p28 and EBI3. Functioning as a linkage between innate and adaptive immunity, IL-27 is mainly produced by activated antigen-presenting cells and has a variety of responder cells including T cells, NK cells, macrophages and dendritic cells. IL-27 plays an antitumor role through promoting the production of cytotoxic T cells, regulating the differentiation of T cell subsets, enhancing the function of NK cells and inhibiting the angiogenesis. On the other hand, IL-27 may also have a positive effect on tumor progress and metastasis. IL-27 can be used as a reference marker for tumor diagnosis, due to its relation to the occurrence and development of tumors. This article reviews the research progress on the roles of IL-27 in tumor biological regulation.
